Manufacturing, Gene Therapies

Lilly Launches Institute for Genetic Medicine and Invests in Boston Seaport Site

February 24, 2022

Eli Lilly and Company are investing $700 million into a Boston-based facility for the newly announced Institute for Genetic Medicine.

Thermo Fisher Scientific Unveils New CGT Services

February 16, 2022

Thermo Fisher Scientific's solution for cell and gene therapies involves a combination of cold chain logistics, serialization compliance, and distribution

Intellia Therapeutics Acquires Rewrite Therapeutics

February 07, 2022

The acquisition will include Rewrite’s DNA writing platform, expanding Intellia’s genome editing tools.

Piramal Pharma Invests Minority Stake in India-Based CDMO, Yapan Bio

January 05, 2022

With this investment into Yapan Bio, Piramal Pharma adds new technologies and capabilities in large molecules, including vaccines and gene therapies, to its global offering.

Genezen Starts Up Operations at Lenti- and Retroviral Vector Process Development Lab

December 17, 2021

Genezen has opened its new process development and analytical lab for viral vector production.

Pfizer Opens Gene Therapy Clinical Manufacturing Facility

December 16, 2021

Pfizer invested $68.5 million in a facility in Durham, NC.

New Isolator for Cell and Gene Therapy Manufacturing

December 13, 2021

SKAN’s new Cellana isolator is designed for GMP manufacturing of ATMPs.

ISPE Publishes Guide for ATMP Facilities

December 10, 2021

Guide addresses challenges of applying GMPs to autologous cell therapy manufacturing.

Taiyo Pharma Tech Adds Gene Therapy Capacity in Japan

December 09, 2021

A new Cytiva FlexFactory platform will be installed at Taiyo Pharma Tech’s site in Osaka, Japan.

Contamination Control for Cell and Gene Therapies Needs New Analytics

December 01, 2021

Analytical methods need a boost to ensure quality control for cell and gene therapies.